{
  "context": {
    "rules": [
      "Rule1: If vaccineX is approved in phase 1, then vaccineX is effective.",
      "Rule2: Whenever the alpha variant is detected, approval for vaccineX is not rejected.",
      "Rule3: Provided that the delta variant is detected, approval for vaccineX is not rejected.",
      "Rule4: Under the condition that the trial for vaccineX is resumed, it is not the case that the trial for vaccineX is suspended.",
      "Rule5: If supply is available in regionA, then vaccineX is effective.",
      "Rule6: Whenever supply is available in regionB, vaccineX is effective.",
      "Rule7: If a shipment has been distributed to regionA, then supply is available in regionA.",
      "Rule8: Either a shipment has been distributed to regionA or a shipment has been distributed to regionB.",
      "Rule9: If vaccineX is approved in phase 2, then vaccineX is effective.",
      "Rule10: Under the condition that the outbreak in regionB is contained, it is not the case that the outbreak in regionA is contained.",
      "Rule11: If the schedule for vaccineX is adjusted, then the dosage for vaccineX is modified.",
      "Rule12: If the agency has recommended an adjustment, then if it is not the case that either the alpha variant is not detected or the delta variant is not detected implies the protocol for vaccineX is updated, then the schedule for vaccineX is adjusted.",
      "Rule13: Either the agency has recommended an adjustment or the agency has opposed an adjustment.",
      "Rule14: Whenever the agency has opposed an adjustment, then if it is not the case that either the alpha variant is not detected or the delta variant is not detected implies the protocol for vaccineX is updated, then the schedule for vaccineX is adjusted.",
      "Rule15: If a booster for vaccineX has been developed, then the protocol for vaccineX is updated.",
      "Rule16: Provided that the booster for vaccineX has been tested, a booster for vaccineX has been developed.",
      "Rule17: Either a modification for vaccineX has been approved or a modification for vaccineX has been rejected.",
      "Rule18: If the trial for vaccineX has been initiated, then either vaccineX is approved in phase 1 or vaccineX is approved in phase 2.",
      "Rule19: The trial for vaccineX has been initiated or the trial for vaccineX has been completed.",
      "Rule20: Whenever a modification for vaccineX has been rejected, then if a mutation in the spike protein has been identified, then if either the alpha variant is not detected or the delta variant is not detected, the booster for vaccineX has been tested.",
      "Rule21: Either the patent for vaccineX has expired or if a modification for vaccineX has been approved, then if a mutation in the spike protein has been identified, then if either the alpha variant is not detected or the delta variant is not detected, the booster for vaccineX has been tested.",
      "Rule22: If the patent for vaccineX has been renewed, then it is not the case that the patent for vaccineX has expired.",
      "Rule23: Provided that an application for renewal has been filed, then if the patent for vaccineX is not renewed, the license for vaccineX has been extended.",
      "Rule24: Either an application for renewal has been filed or the application for renewal has been withdrawn.",
      "Rule25: If the application for renewal has been withdrawn, then if the patent for vaccineX is not renewed, the license for vaccineX has been extended.",
      "Rule26: Under the condition that a batch of booster has been produced, the protocol for vaccineX is updated.",
      "Rule27: If a batch of booster has been shipped, then a batch of booster has been produced.",
      "Rule28: Whenever doses have been allocated to regionA, supply is available in regionA.",
      "Rule29: Provided that doses have been allocated to regionB, supply is available in regionB.",
      "Rule30: Whenever the trial for vaccineX has been completed, the application for vaccineX has been submitted.",
      "Rule31: Provided that supplies have been delivered to regionA, doses have been allocated to regionA.",
      "Rule32: Either supplies have been delivered to regionA or supplies have been delivered to regionB.",
      "Rule33: If supplies have been delivered to regionB, then doses have been allocated to regionB.",
      "Rule34: If an endemic phase has been announced, then if it is not the case that coverage target has been reached implies immunity threshold has been achieved, diseaseX has been declared endemic.",
      "Rule35: Either an endemic phase has been announced or the endemic claim has been disputed.",
      "Rule36: If the endemic claim has been disputed, then the endemic assessment has been challenged.",
      "Rule37: Under the condition that the endemic assessment has been challenged, the endemic decision has been appealed.",
      "Rule38: If the endemic decision has been appealed, then if it is not the case that coverage target has been reached implies immunity threshold has been achieved, diseaseX has been declared endemic.",
      "Rule39: Whenever the data for vaccineX has been analyzed, then either vaccineX is approved in phase 1 or vaccineX is approved in phase 2.",
      "Rule40: If the committee has reviewed vaccineX, then the data for vaccineX has been analyzed.",
      "Rule41: Provided that the application for vaccineX has been submitted, the committee has reviewed vaccineX.",
      "Rule42: Under the condition that emergency authorization has been granted for vaccineX, vaccineX is effective.",
      "Rule43: Either approval for vaccineX has been rejected or emergency authorization has been granted for vaccineX.",
      "Rule44: Under the condition that either the alpha variant is not detected or the delta variant is not detected, a batch of booster has been shipped.",
      "Rule45: Whenever either the alpha variant is not detected or the delta variant is not detected, it is not the case that the protocol for vaccineX is updated.",
      "Rule46: If it is not the case that if either the alpha variant is not detected or the delta variant is not detected then the protocol for vaccineX is updated, then the trial for vaccineX has been suspended.",
      "Rule47: Under the condition that it is not the case that if either the alpha variant is not detected or the delta variant is not detected then the protocol for vaccineX is updated, the trial for vaccineX has been resumed.",
      "Rule48: Under the condition that it is not the case that if either the alpha variant is not detected or the delta variant is not detected then the protocol for vaccineX is updated, it is not the case that the dosage for vaccineX has been modified.",
      "Rule49: If it is not the case that if it is not the case that if a shipment has been distributed to regionB then supply is available in regionB then distribution of vaccineX has been delayed, then the outbreak in regionA has been contained.",
      "Rule50: Whenever it is not the case that if it is not the case that if a shipment has been distributed to regionB then supply is available in regionB then distribution of vaccineX has been delayed, the outbreak in regionB has been contained.",
      "Rule51: Under the condition that it is not the case that if it is not the case that if a shipment has been distributed to regionB then supply is available in regionB then distribution of vaccineX has been delayed, coverage target has been reached.",
      "Rule52: Whenever it is not the case that if it is not the case that if a shipment has been distributed to regionB then supply is available in regionB then distribution of vaccineX has been delayed, it is not the case that immunity threshold has been achieved.",
      "Rule53: If the patent for vaccineX is not renewed, then it is not the case that the license for vaccineX has been extended."
    ],
    "facts": [
      "Fact1: A mutation in the spike protein has been identified.",
      "Fact2: It is not the case that distribution of vaccineX has been delayed.",
      "Fact3: DiseaseX has not been declared endemic."
    ]
  },
  "question": "VaccineX is effective."
}